CHEPLAPHARM Arzneimittel GmbH
support_agent

Your contact persons

Investors Domain Investor Relations Archive

12/16/2020

CHEPLAPHARM proves its vigour

more chevron_right
Investor Relations Archive

10/08/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €575 Million 4.375% Senior Secured Notes due 2028 $500 Million 5.500% Senior Secured Notes due 2028


more chevron_right
Investors Domain Archive

06/22/2020

CHEPLAPHARM acquires two product portfolios

Greifswald, 06/22/2020


more chevron_right
Archive

05/15/2020

CHEPLAPHARM wins again

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed Companies Award' for the second time in a row.…


more chevron_right
Investor Relations Archive Press releases

01/29/2020

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding, following its last capital market transaction in May…


more chevron_right
Investor Relations Archive

01/28/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of 100.0%.


more chevron_right
Archive Investor Relations

01/23/2020

CHEPLAPHARM announces offering of Senior Secured Notes

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.


more chevron_right
Investor Relations Archive

06/19/2018

CHEPLAPHARM receives credit ratings: A premiere for a medium-sized company in Mecklenburg-Western Pomerania

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.


more chevron_right
Archive

08/09/2017

Mysimba®: Commercialization and distributorship arrangement with Orexigen Therapeutics Ireland, Ltd.

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement covering Germany, France and Austria for Mysimba®…


more chevron_right
Archive

02/24/2017

50 new employees: CHEPLAPHARM’s successful story continues

The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight months.


more chevron_right
Back to top expand_less